The Construction and Analysis of ceRNA Network and Immune

1

Infiltration in Kidney Renal Clear Cell Carcinoma 2 3 Lugang Deng ¹, Zhi Qu ², Peixi Wang ², Nan Liu ^{1, 2, 3, *} 4 5 ¹ School of Public Health, Guangzhou Medical University, Guangzhou, 511436, P. R. 6 7 China ² Institute of Chronic Disease Risks Assessment, School of Nursing and Health, 8 9 Henan University, Kaifeng, 475004, P. R. China 10 ³ Pinghu Hospital, Health Science Center, Shenzhen University, Shenzhen, 518116, P. 11 R. China. 12 13 *Corresponding author: 14 Nan Liu 15 13688869875@163.com ORCID: orcid.org/0000-0002-8895-3169 16 17 18 19 20 21 22

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

Abstract Background: Kidney renal clear cell carcinoma (KIRC) has the highest invasion, mortality and metastasis of the renal cell carcinomas and seriously affects patients' quality of life. However, the composition of the immune microenvironment and regulatory mechanisms at transcriptomic level such as ceRNA of KIRC are still unclear. **Methods:** We constructed a ceRNA network associated with KIRC by analyzing the long noncoding RNA (lncRNA), miRNA and mRNA expression data of 506 tumor tissue samples and 71 normal adjacent tissue samples downloaded from the Cancer Genome Atlas (TCGA) database. In addition, we estimated the proportion of 22 immune cell types in these samples through "The Cell Type Identification by Estimating Relative Subsets of RNA Transcripts". Based on the ceRNA network and immune cells screened by univariate Cox analysis and Lasso regression, two nomograms were constructed to predict the prognosis of patients with KIRC. Receiver operating characteristic curves (ROC) and calibration curves were employed to assess the discrimination and accuracy of the nomograms. Consequently, co-expression analysis was carried out to explore the relationship between each prognostic gene in a Cox proportional hazards regression model of ceRNA and each survival-related immune cell in a Cox proportional hazards regression model of immune cell types to reveal the potential regulatory mechanism. **Results:** We established a ceRNA network consisting of 12 lncRNAs, 25 miRNAs and 136 mRNAs. Two nomograms containing seven prognostic genes and two immune cells, respectively, were successfully constructed. Both ROC [Area Under

Curves (AUCs) of 1, 3 and 5-year survival in the nomogram based on ceRNA

network: 0.779, 0.747 and 0.772; AUCs of 1, 3 and 5-year survivals in nomogram

based on immune cells: 0.603, 0.642 and 0.607] and calibration curves indicated good accuracy and clinical application value of both models. Through co-correlation analysis between ceRNA and immune cells, we found both LINC00894 and KIAA1324 were positively correlated with follicular helper T (Tfh) cells and negatively correlated with resting mast cells.

Conclusions: Based on the ceRNA network and tumor-infiltrating immune cells, we constructed two nomograms to predict the survival of KIRC patients and demonstrated their value in improving the personalized management of KIRC.

Keywords: Kidney renal clear cell carcinoma; TCGA; Competing endogenous RNA network; Immune cell; Prognosis

Introduction

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

Renal cell carcinoma is a malignant kidney tumor that the American Cancer Society reports was diagnosed in 65,340 patients, and caused 14,970 deaths, in the United States during 2018 (1). It is a serious health problem worldwide, and the economic burden of the disease has steadily increased during the last century (2). Kidney renal clear cell carcinoma (KIRC) is the subtype of renal cell carcinoma with the highest invasiveness, mortality and metastasis rates (3); it is typically screened and diagnosed through computed tomography (CT), magnetic resonance imaging (MRI) and pathological section testing in the clinic (4). Several difficulties continue to make KIRC a challenge to treat, including its stealth in early stages, a lack of effective biomarkers, radiation risks and the high cost of diagnostic imaging required. Underlying biomarkers and molecular mechanisms for the prevention, diagnosis and prognosis of KIRC require further studies. Long noncoding RNAs (lncRNAs) contain more than 200 nucleotides without the function of encoding proteins and have achieved attention recently because of their potential for exploring novel biomarkers in diseases and for elucidating mechanisms of biological processes (5, 6). Current research reveals that lncRNA plays an important role in the genesis and development of tumors through interactions with competing endogenous RNA (ceRNA) or by acting as microRNA sponges (7). Tumor-infiltrating immune cells are a major component of the tumor microenvironment and affect the clinical outcomes and pathological staging of multiple tumor types (8, 9). Some studies suggest lncRNA can affect tumor development and tumor immune cell microenvironment through the ceRNA network (10-12). Therefore, exploring interactions between the ceRNA network and various immune cells in the development of KIRC is essential.

In this study, we construct a ceRNA network related to the occurrence and development of KIRC using transcriptome and clinical data from the Cancer Genome Atlas (TCGA) to explore potential molecular mechanisms. In addition, we used "The Cell Type Identification by Estimating Relative Subsets of RNA Transcripts algorithm" (CIBERSORT) algorithm to assess differences in the composition of immune cells within tumor tissues and normal tissues. Furthermore, predictive nomograms were constructed based on the ceRNA network and on significant immune cells. Finally, we evaluated the relationship between tumor-infiltrating immune cells and the ceRNA network to identify the underlying regulatory mechanisms.

Materials and methods

Data source and selection

A flowchart illustrating the research process of our study is provided in Figure 1. Data on lncRNA, miRNA and mRNA expression of KIRC patients were downloaded from the Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/) through the GDC data transfer tool. Relevant clinical information including age, gender, survival data (vital status, days to death and days to last follow-up), grade and TNM stage of tumor tissues was also obtained for further analysis. We excluded samples with incomplete survival or pathological staging data, as well as duplicate samples. Only samples with both mRNA and miRNA expression profiles were included in this study. Correspondingly, the adjacent and paired normal tissues collected from the included patients was setted as the control group.

Figure 1

Differential expression analysis

Based on the HTSeq-Counts data of included samples, we used the "DESeq2"

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

package (13) (http://bioconductor.org/packages/DESeq2/) of Bioconductor to screen for differentially expressed lncRNAs (DElncRNAs), miRNAs (DEmiRNAs) and mRNAs (DEmRNAs) between KIRC tissue and normal adjacent tissue. The log fold change (FC) criterion for differential expression was set as $|\log_2(FC)| > 1$ and the false discovery rate (FDR) at < 0.05. For the differential expression results of each type of RNA, volcano plots and heatmaps were generated through R packages "ggpolt2" and "pheatmap." Construction of lncRNA-miRNA-mRNA ceRNA network and survival analysis Using the differential expression results, we predicted the miRNAs-lncRNAs interactions and the miRNAs-mRNAs interactions based on the starBase v2.0 database (14, 15) (http://starbase.sysu.edu.cn/starbase2/index.php), which contained the miRNA-target interactions overlapped with CLIP-Seq data. We conducted hypergeometric tests and correlation analysis to filter the predicted interactions with FDR < 0.05 as the screening criteria. In addition, the lncRNA-miRNA-mRNA regulatory network of KIRC was visualized using Cytoscape v.3.8.1 (http://cytoscape.org/) (16). Besides, we conducted a Kaplan-Meier (K-M) survival curve analysis to assess the prognostic value of genes in the KIRC ceRNA network. ceRNA network: Cox proportional hazards regression model Firstly, significant variables were screened for integration into the initial Cox model using univariate Cox analysis. Next, a least absolute shrinkage and selection operator (Lasso) regression was employed to further evaluate the fitness of multifaceted models and filter variables. Finally, we generated a nomogram of from multivariate Cox proportional hazards regression models to predict the prognosis of KIRC patients. To confirm the discrimination and precision of the nomogram, receiver operating characteristic curves (ROC) and calibration curves were employed. In addition, we

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

calculated the risk score of each patient and then divided patients into high and low risk groups based on the median to conduct a K-M survival curve analysis. Tumor-infiltrating immune cells: CIBERSORT estimation and survival analysis To analyze differences between the two groups at the level of immune cells, and explore the connection between key biomarkers in the ceRNA network and immune cells, we estimated the proportion of 22 kinds of immune cell types in 506 tumor tissues and 71 normal adjacent tissues by **CIBERSORT** (17)(http://cibersort.stanford.edu/), an algorithm for characterizing cell composition of complex tissues from their gene expression profiles. Only samples with CIBERSORT output of P < 0.05 were included in further analysis. After screening samples, we searched for immune cells with significant differences between cancer tissues and normal adjacent tissues, as indicated by a Wilcoxon rank-sum test. A K-M survival curve analysis was performed to evaluate the relationship between the content of different immune cells and the overall survival of KIRC patients. Tumor-infiltrating immune cells: Cox proportional hazards regression model Immune cells with significant effects in univariate Cox analysis were integrated into the initial Cox model and the Lasso regression again used to evaluate the fitness of multifaceted models and filter variables further. As above, we constructed a nomogram based on the multivariate model of immune cells, and used ROC and calibration curves to confirm the discrimination and precision of the nomogram. Similarly, we conducted a K-M survival curve analysis by dividing patients into high and low risk groups according to the median of risk score. Finally, a Pearson correlation analysis was used to explore the relationship between genes and immune cells.

160

161

162

163

164 165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

Statistical Analysis Only two-sided P-values < 0.05 was considered statistically significant. All statistical analyses were conducted in R version 4.0.2 software (Institute for Statistics and Mathematics, Vienna, Austria; www.r-project.org) (packages: corrplot, DESeq2, GDCRNATools, ggplot2, glmnet, pheatmap, rms, survival, survminer, timeROC). Results Differential expression in lncRNAs, miRNAs and mRNAs After screening the samples of TCGA-KIRC, we constructed an experimental group and a control group containing of 506 tumor tissues and 71 normal adjacent tissues, respectively. Compared to the control group, we identified 357 DElncRNAs (287 up-regulated and 70 down-regulated), 132 DEmiRNAs (61 up-regulated and 71 down-regulated) and 3092 DEmRNAs (2032 up-regulated and 1060 down-regulated) using the cutoffs of the $|\log_2(FC)| > 1$ and FDR < 0.05 (Figure 2a-g). Figure 2 Figure 3 Table 1 Construction of lncRNA-miRNA-mRNA ceRNA network and survival analysis Using the starBase v2.0 database and ceRNA theory, a lncRNA-miRNA-mRNA ceRNA network consisting of 173 genes (12 lncRNAs, 25 miRNAs and 136 mRNAs) was established (Figure 3a and Table 1). A K-M survival curve analysis to assess the prognostic value of nodes in the ceRNA network revealed 83 genes (10 lncRNAs, 7 miRNAs and 66 mRNAs) related to the overall survival of KIRC patients. Survival curves of the top three (according to P-value) lncRNAs (PVT1, AC005154.1, AC015813.1), miRNAs (hsa-miR-21-5p, hsa-miR-130b-3p, hsa-miR-204-5p), and mRNAs (MXD3, VPS13D, KCNN4) are shown in Figures 3b-d, e-g and h-j, respectively.

ceRNA network: Cox proportional hazards regression model

Univariate Cox analysis applied to filter genes in the ceRNA network retained 97 genes for incorporation into the initial model (Table S1). Lasso regression analysis indicated that 15 genes were statistically significant in this model. Subsequently, a Cox proportional hazards regression model with seven genes was established through further screening of key genes based on the Akaike Information Criterion (AIC). Finally, we constructed a nomogram to predict the 1, 3 and 5-year overall survival probability of KIRC patients. ROC [Area Under Curves (AUCs)] for the model gave 1, 3 and 5-year survivals of 0.779, 0.747 and 0.772, respectively, which reflected the discrimination and precision of the nomogram with calibration curves (Figure 4). Overall survival (based on K-M curves) of the high-risk group is lower than that of the low-risk group (Figure S1). Survival curves of the genes in the model are also provided in Figure S1.

Figure 4

Tumor-infiltrating immune cells: CIBERSORT estimation and survival analysis

The analysis by CIBERSORT identified five normal tissue samples and 206 tumor tissue samples for inclusion in subsequent analysis (P < 0.05) and the proportions of 22 immune cells in each sample are displayed in the histogram and heat map of Figure 5. A Wilcoxon rank-sum test showed that naive B cells (P < 0.001), plasma cells (P < 0.001), CD8 T cells (P = 0.014), CD4 naive T cells (P < 0.001), CD4 memory resting T cells (P = 0.013), regulatory (Tregs) T cells (P = 0.015), gamma delta T cells (P = 0.021), resting dendritic cells (P = 0.016) and resting mast cells (P = 0.016) 0.048) all varied between the two tissue sample types (Figure 5c). Based on the results of K-M survival curve analysis, five immune cells, including memory B cells, plasma

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

cells, follicular helper T (Tfh) cells, T regulatory (Tregs) cells and resting mast cells were related to overall survival of KIRC patients (Figure S2). The clinical correlation of 22 immune cells is displayed in Figure S3. Figure 5 Tumor-infiltrating immune cells: Cox proportional hazards regression model After filtering based on univariate Cox analyses (Table S2), two of 22 immune cells (Tfh and resting mast cells) were incorporated into the initial regression model. Lasso regression analysis and AIC were then employed for further optimization of the model, and both cells were kept in the final Cox proportional hazards regression model. A nomogram was developed to predict the 1, 3 and 5-year overall survival probability of KIRC patients based on the model. Both the ROC (AUCs of 1, 3 and 5-year survivals: 0.603, 0.642 and 0.607) and the calibration curves suggested that the nomogram had good accuracy (Figure 6). The K-M survival curves suggested that significant differences existed in the overall survival of the high versus low-risk group (Figure S4). Figure 6 Co-expression analysis of key genes and immune cells Pearson correlation analysis was used to explore the co-expression pattern between 22 types of immune cells (Figure 7a). Similarly, the co-expression relationship between the key biomarkers and immune cells of the two models is illustrated in Figure 7b. Tfh cells are positively correlated with LINC00894 (Figure 7c, R = 0.36, P < 0.001) and KIAA1324 (Figure 7d, R = 0.39, P < 0.001), while resting mast cells are negatively correlated with LINC00894 (Figure 7e, R = -0.32, P < 0.001) and KIAA1324 (Figure 7f, R = -0.30, P < 0.001). Figure 7

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

Validation of the correlation between key genes and immune cells Multiple databases were searched to verify the correlation between the key genes (LINC00894 and KIAA1324) and immune cells (Tfh cells and resting mast cells) identified. B cell lymphoma 6 (BCL6), CXCL13, CD10 (MME), ICOS and PD-1 (PDCD1) were the most common surface markers of Tfh cells in the CellMarker database (Figure S5). In the OncomineTM platform, we explored the expression of KIAA1324 and Tfh markers among various cancers. KIAA1324, BCL6, CXCL13, ICOS and PDCD1 were highly expressed and MME was downregulated in KIRC compared to normal kidney tissue (Figure S6); median rank and P-values are listed in Table S3. Using the Gene Expression Profiling Interactive Analysis (GEPIA), KIAA1324 is positively correlated with CXCL13, ICOS and PDCD1 in KIRC (Figure S7), and LINC00894 is positively correlated with BCL6, ICOS and PDCD1 in KIRC (Figure S8). Similarly, the results of the LinkedOmics database showed that KIAA1324 was positively correlated with BCL6, CXCL13, ICOS and PDCD1 in KIRC. In addition, the expression of KIAA1324 was significantly different among tumor stages and related to tumor purity in KIRC (Figure S9). **Discussion** KIRC is one of the most common and malignant subtypes of kidney tumors (3). However, because of limitations in early detection and a lack of sensitive biomarkers, patients with KIRC typically have a poor prognosis. Recently, ceRNA was identified as playing a potentially important role in the molecular regulatory function of tumorigenesis and growth, and in affecting differences in immune-infiltrating cells within multiple tumors. In this study, we investigated the role and connection of the

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

ceRNA network and immune infiltration in KIRC to explore key prognostic biomarkers and potential regulatory mechanisms. We established a ceRNA network consisting of 12 lncRNAs, 25 miRNAs and 136 mRNAs and compared the composition differences of immune cells related to KIRC. Based on the results, two prediction nomograms consisting of seven genes and two immune cells, respectively, were constructed to evaluate overall survival. A correlation analysis of the key factors in both nomograms indicated that both LINC00894 (lncRNA) and KIAA1324 (protein-coding RNA) were positively correlated with Tfh cells and negatively correlated with resting mast cells. Consequently, we infer that ceRNA regulatory function, in which both LINC00894 and KIAA1324 participate, and Tfh cells and resting mast cells may play a crucial role in the development and treatment of KIRC. LINC00894 is lncRNA derived from a locus on the X chromosome that is differentially expressed in various cancers (18). Similar to our work, Liang (19) reported that LINC00894 was a tumor-special lncRNA in KIRC that was upregulated in tumor tissues and correlated with overall survival time. Epithelial-to-mesenchymal transition (EMT) regulating miRNAs regulate drug resistance and cancer progression and metastasis (20, 21). LINC00894 can inhibit the TGF-β2/ZEB1 signaling pathway by acting as the sponge of EMT-regulating miR-200, or can be upregulated by ERα activation and positively regulate the expression of miR-200a-3p and miR-200b-3p, which results in induction of the TGF-β2/ZEB1 signaling pathway to reduce the occurrence of drug resistance in breast cancers (18, 22, 23). In our study, LINC00894 might suppress the expression of hsa-miR-342-3p, which has an important role in progression, staging and metastasis of various cancers (24-27). In view of the upregulation of hsa-miR-342-3p contributing to gefitinib resistance via targeting

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

CPA4 in non-small cell lung cancer (28), we speculate that LINC00894 is involved in the progression of cancer and may be a promising treatment target to eliminate drug resistance in patients with KIRC. KIAA1324, also known as EIG121, encodes a 1013 amino acid transmembrane protein that shows high sequence conservation among different species. In type I endometrial cancer (estrogen-related), the expression of KIAA1324 is upregulated, but it is downregulated in type II endometrial cancer (not estrogen-related), which is more malignant than type I (29). KIAA1324 may be a novel suppressor, being epigenetically downregulated in gastric cancer (30); in addition, its high expression in endometrial and pancreatic carcinoma predicts improved survival (31, 32). However, increased expression of KIAA1324 in ovarian cancer is associated with a poor prognosis (33). These studies indicate that KIAA1324 may exhibit different biological functions in various cancers. Furthermore, recent mechanistic studies reveal that KIAA1324 is localized to endosome-lysosome compartments and associated with autophagy, which helps protect cells from cell death by upregulating the autophagy pathway under unfavorable conditions, such as starvation or chemotherapy (34). Therefore, we infer that overexpressed KIAA1324 helps cancer cells proliferate and resist chemotherapy in KIRC. In this study, we explored five among 22 types of immune cells related to patient prognosis, and screened out the Tfh cells and resting mast cells to construct a Cox proportional hazards regression model, which evaluation of its AUC suggests has clear clinical value. Gou et al. (35) also explored the relationship between immune cells and renal cell carcinoma, and similar to our research, found Tfh cells were associated with poor prognosis and resting mast cells were positively associated with long term survival.

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

Under the action of myeloid professional antigen presenting cells (APC), naive CD4+ T cells could differentiate into Tfh cells and non-Tfh effector cells (such as Th1, Th2, or Th17 cells) (36). Therefore, Tfh cells are a specialized subset of CD4+ T cells that help B cells respond to antigens (37), which is, in turn, depends on the expression of transcriptional factor B cell lymphoma 6 (BCL6) (38). In the past decade, several studies have revealed a potential connection between Tfh cells and infiltrated tumors. Amé-Thomas et al. (39) demonstrated that Tfh cells protect follicular lymphoma malignant B cells from spontaneous and rituximab-induced apoptosis by upregulating CD40L and IL-4, which might lead to a worse prognosis. In non-small cell lung cancer (NSCLC) tumor tissues, the proportion of Tfh cells is increased, suggesting that Tfh cells might play an important role in estimating the poor survival of NSCLC patients (40). In addition, Tfh cell abundance is known to improve prognosis of patients with breast cancer or colorectal cancer (41, 42), which indicates the value of Tfh cells against tumors through immune responses. Mast cells, both resting and activated, are large granulated innate immune cells found predominantly in sites between the host and its external environment, such as skin, respiratory mucosa, and the gastrointestinal tract (43). The activation of mast cells is related to various stimuli received by numerous receptors on the cell surface, such as pathogens, neuropeptides, cytokines, growth factors, toxins, basic compounds, complement, immune complexes, etc. (44). Recent studies have shown that the association between mast cells and cancer is two-sided, including both involvement in, and protection against, tumor progression. Xu et al. (45) constructed a prognosis-associated microRNA-mast cell network in lung adenocarcinoma, and found resting mast cell numbers were closely related to better overall survival and disease-free survival (DFS), while activated mast cells were related to poor survival.

miR-30a and miR-550a are also involved in the regulation of immune response by acting as the promoter and suppressor of resting mast cells, respectively. In contrast, mast cells in hepatocellular carcinoma are mostly resting, inactivation of mast cells can promote immune escape, which is beneficial to tumor growth (46). Our research inevitably has some limitations that should be recognized. First, our research data was obtained from public databases. The limited data means that the clinical pathological parameters are incomplete, which can lead to potential errors and biases. Secondly, we have not taken the heterogeneity of the immune microenvironment associated with the location of immune infiltration into consideration. In other words, the accuracy and applicability of the prediction models will be affected by the heterogeneity of tissue subtypes. In addition, the data series used in this study are all from Western countries, so applying the research conclusions to Asian countries has certain bias and may be inappropriate. As well, the lack of cell markers for resting mast cells leads to incomplete validation in our study. Lastly, this study is not a biological mechanism research, as it lacks experiments on the interaction mechanisms between ceRNA and immune cells. Despite limitations of the study, we did combine tumor infiltrating immune cells with a ceRNA network for analysis in KIRC, which not only constructed two normograms with clinical predictive value, but also identified a correlation between two key prognostic molecules and two prognosis-related immune cells, providing novel directions for future research.

Conclusions

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

Based on tumor-infiltrating immune cells and ceRNA networks, we constructed two nomograms to predict survival of KIRC patients. The high AUC values we obtained

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

reflect the utility of this approach, which provides clinicians with more comprehensive clinical information through the models to improve individual management of KIRC patients. In addition, our study suggests that LINC00894, KIAA1324, Tfh cells and resting mast cells are significantly related to the prognosis of KIRC patients and we infer that LINC00894 and KIAA1324 might interact with Tfh cells and resting mast cells to affect the progression of KIRC. This study also provides new ideas for the pathogenesis and clinical treatment of KIRC. **Author contribution** ZQ and NL conceived the idea and designed the study. LD conducted the data analysis and visualization. PW performed the data interpretation and literature collection. LD and NL wrote the manuscript. ZQ and NL contributed to the revision of the manuscript draft. All authors read and approved the final manuscript. Data availability statement The dataset (TCGA-KIRC) analyzed in this study is publicly available in TCGA (https://tcga-data.nci.nih.gov/tcga/). **Declaration of competing interest** We declare that no potential competing interests exist.

Acknowledgement

381

390

391

- 382 This work was supported by National Natural Science Foundation of China (No.
- 383 81872584) and (No. 81472941), National 863 Young Scientist Program (No.
- 384 2015AA020940), Key Scientific Research Project Plan of Henan Province (No.
- 385 21A330001), Natural Science Foundation of Guangdong Province (No.
- 386 2016A030313138), Key Projects of Guangzhou Science and Technology Program
- 387 (No. 201704020056), Interdisciplinary Research for First-class Discipline
- 388 Construction Project of Henan University (No. 2019YLXKJC04) and Scientific
- Research Project for University of Education Bureau of Guangzhou (No. 201831841).

References

- 392 1. R. L. Siegel, K. D. Miller and A. Jemal: Cancer statistics, 2018. CA: A Cancer
- 393 Journal for Clinicians, 68(1), 7-30 (2018) doi:10.3322/caac.21442
- 394 2. J. J. Hsieh, M. P. Purdue, S. Signoretti, C. Swanton, L. Albiges, M. Schmidinger,
- 395 D. Y. Heng, J. Larkin and V. Ficarra: Renal cell carcinoma. *Nature Reviews Disease*
- 396 *Primers*, 3(1), 17009 (2017) doi:10.1038/nrdp.2017.9
- 397 3. W. Xiao, X. Wang, T. Wang and J. Xing: Overexpression of BMP1 reflects poor
- 398 prognosis in clear cell renal cell carcinoma. Cancer gene therapy, 27(5), 330-340
- 399 (2020) doi:10.1038/s41417-019-0107-9
- 400 4. J. J. Morrissey, V. M. Mellnick, J. Luo, M. J. Siegel, R. S. Figenshau, S. Bhayani
- 401 and E. D. Kharasch: Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations
- 402 as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study.
- 403 *JAMA Oncology*, 1(2), 204-212 (2015) doi:10.1001/jamaoncol.2015.0213
- 404 5. T. Nagano and P. Fraser: No-Nonsense Functions for Long Noncoding RNAs.
- 405 *Cell*, 145(2), 178-181 (2011) doi:https://doi.org/10.1016/j.cell.2011.03.014
- 406 6. J. J. Quinn and H. Y. Chang: Unique features of long non-coding RNA biogenesis
- 407 and function. *Nature Reviews Genetics*, 17(1), 47-62 (2016) doi:10.1038/nrg.2015.10
- 408 7. Y. Tay, J. Rinn and P. P. Pandolfi: The multilayered complexity of ceRNA
- 409 crosstalk and competition. *Nature*, 505(7483), 344-352 (2014)
- 410 doi:10.1038/nature12986

- 411 8. W. Hong, Y. Gu, R. Guan, D. Xie, H. Zhou and M. Yu: Pan-cancer analysis of the
- 412 CASP gene family in relation to survival, tumor-infiltrating immune cells and
- 413 therapeutic targets. *Genomics*, 112(6), 4304-4315 (2020)
- 414 doi:https://doi.org/10.1016/j.ygeno.2020.07.026
- 415 9. Y. Gao, S. Chen, S. Vafaei and X. Zhong: Tumor-Infiltrating Immune Cell
- 416 Signature Predicts the Prognosis and Chemosensitivity of Patients With Pancreatic
- 417 Ductal Adenocarcinoma. Frontiers in oncology, 10, 557638-557638 (2020)
- 418 doi:10.3389/fonc.2020.557638
- 419 10. M. Xu, X. Xu, B. Pan, X. Chen, K. Lin, K. Zeng, X. Liu, T. Xu, L. Sun, J. Qin, B.
- 420 He, Y. Pan, H. Sun and S. Wang: LncRNA SATB2-AS1 inhibits tumor metastasis and
- 421 affects the tumor immune cell microenvironment in colorectal cancer by regulating
- 422 SATB2. Molecular Cancer, 18(1), 135 (2019) doi:10.1186/s12943-019-1063-6
- 423 11. D. Huang, J. Chen, L. Yang, Q. Ouyang, J. Li, L. Lao, J. Zhao, J. Liu, Y. Lu, Y.
- 424 Xing, F. Chen, F. Su, H. Yao, Q. Liu, S. Su and E. Song: NKILA lncRNA promotes
- 425 tumor immune evasion by sensitizing T cells to activation-induced cell death. *Nature*
- 426 *Immunology*, 19(10), 1112-1125 (2018) doi:10.1038/s41590-018-0207-y
- 427 12. J. Cao, R. Dong, L. Jiang, Y. Gong, M. Yuan, J. You, W. Meng, Z. Chen, N.
- 428 Zhang, Q. Weng, H. Zhu, Q. He, M. Ying and B. Yang: LncRNA-MM2P Identified as
- 429 a Modulator of Macrophage M2 Polarization. Cancer Immunology Research, 7(2),
- 430 292-305 (2019) doi:10.1158/2326-6066.Cir-18-0145
- 431 13. M. I. Love, W. Huber and S. Anders: Moderated estimation of fold change and
- dispersion for RNA-seq data with DESeq2. Genome Biology, 15(12), 550 (2014)
- 433 doi:10.1186/s13059-014-0550-8
- 434 14. J.-H. Li, S. Liu, H. Zhou, L.-H. Qu and J.-H. Yang: starBase v2.0: decoding
- 435 miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from
- 436 large-scale CLIP-Seq data. Nucleic Acids Research, 42(D1), D92-D97 (2014)
- 437 doi:10.1093/nar/gkt1248
- 438 15. J.-H. Yang, J.-H. Li, P. Shao, H. Zhou, Y.-Q. Chen and L.-H. Qu: starBase: a
- 439 database for exploring microRNA-mRNA interaction maps from Argonaute
- 440 CLIP-Seq and Degradome-Seq data. *Nucleic Acids Research*, 39(suppl_1),
- 441 D202-D209 (2011) doi:10.1093/nar/gkq1056
- 16. P. Shannon, A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin,
- 443 B. Schwikowski and T. Ideker: Cytoscape: a software environment for integrated
- 444 models of biomolecular interaction networks. Genome research, 13(11), 2498-2504
- 445 (2003) doi:10.1101/gr.1239303
- 446 17. A. M. Newman, C. L. Liu, M. R. Green, A. J. Gentles, W. Feng, Y. Xu, C. D.
- Hoang, M. Diehn and A. A. Alizadeh: Robust enumeration of cell subsets from tissue
- 448 expression profiles. *Nature methods*, 12(5), 453-457 (2015) doi:10.1038/nmeth.3337
- 449 18. X. Zhang, M. Wang, H. Sun, T. Zhu and X. Wang: Downregulation of
- 450 LINC00894-002 Contributes to Tamoxifen Resistance by Enhancing the TGF-β
- 451 Signaling Pathway. Biochemistry (Moscow), 83(5), 603-611 (2018)
- 452 doi:10.1134/S0006297918050139

- 453 19. T. Liu, J. Sui, Y. Zhang, X. M. Zhang, W. J. Wu, S. Yang, S. Y. Xu, W. W. Hong,
- 454 H. Peng, L. H. Yin, Y. P. Pu and G. Y. Liang: Comprehensive analysis of a novel
- 455 lncRNA profile reveals potential prognostic biomarkers in clear cell renal cell
- 456 carcinoma. *Oncol Rep*, 40(3), 1503-1514 (2018) doi:10.3892/or.2018.6540
- 457 20. A. Ward, A. Balwierz, J. D. Zhang, M. Küblbeck, Y. Pawitan, T. Hielscher, S.
- Wiemann and Ö. Sahin: Re-expression of microRNA-375 reverses both tamoxifen
- resistance and accompanying EMT-like properties in breast cancer. *Oncogene*, 32(9),
- 460 1173-1182 (2013) doi:10.1038/onc.2012.128
- 461 21. S.-M. Park, A. B. Gaur, E. Lengyel and M. E. Peter: The miR-200 family
- determines the epithelial phenotype of cancer cells by targeting the E-cadherin
- 463 repressors ZEB1 and ZEB2. Genes & development, 22(7), 894-907 (2008)
- 464 doi:10.1101/gad.1640608
- 465 22. M. Farhan, M. Aatif, P. Dandawate and A. Ahmad: Non-coding RNAs as
- 466 Mediators of Tamoxifen Resistance in Breast Cancers. In: Breast Cancer Metastasis
- 467 and Drug Resistance: Challenges and Progress. Ed A. Ahmad. Springer International
- 468 Publishing, Cham (2019) doi:10.1007/978-3-030-20301-6_11
- 469 23. L. Huang, G. Liang, Q. Zhang and W. Zhao: The Role of Long Noncoding RNAs
- 470 in Antiestrogen Resistance in Breast Cancer: An Overview and Update. Journal of
- 471 breast cancer, 23(2), 129-140 (2020) doi:10.4048/jbc.2020.23.e10
- 472 24. X. Lai, S. K. Gupta, U. Schmitz, S. Marquardt, S. Knoll, A. Spitschak, O.
- Wolkenhauer, B. M. Pützer and J. Vera: MiR-205-5p and miR-342-3p cooperate in the
- 474 repression of the E2F1 transcription factor in the context of anticancer chemotherapy
- 475 resistance. *Theranostics*, 8(4), 1106-1120 (2018) doi:10.7150/thno.19904
- 476 25. Y. Qin, X. Zhou, C. Huang, L. Li, H. Liu, N. Liang, Y. Chen, D. Ma, Z. Han, X.
- 477 Xu, J. He and S. Li: Serum miR-342-3p is a novel diagnostic and prognostic
- 478 biomarker for non-small cell lung cancer. International journal of clinical and
- 479 *experimental pathology*, 11(5), 2742-2748 (2018)
- 480 26. X. Xue, X. Fei, W. Hou, Y. Zhang, L. Liu and R. Hu: miR-342-3p suppresses cell
- 481 proliferation and migration by targeting AGR2 in non-small cell lung cancer. Cancer
- 482 Letters, 412, 170-178 (2018) doi:https://doi.org/10.1016/j.canlet.2017.10.024
- 483 27. X. Meng, J. Ma, B. Wang, X. Wu and Z. Liu: Long non-coding RNA OIP5-AS1
- promotes pancreatic cancer cell growth through sponging miR-342-3p via AKT/ERK
- signaling pathway. Journal of Physiology and Biochemistry, 76(2), 301-315 (2020)
- 486 doi:10.1007/s13105-020-00734-4
- 487 28. F. Zheng, H. Zhang and J. Lu: Identification of potential microRNAs and their
- 488 targets in promoting gefitinib resistance by integrative network analysis. *Journal of*
- 489 thoracic disease, 11(12), 5535-5546 (2019) doi:10.21037/jtd.2019.11.25
- 490 29. L. Deng, R. R. Broaddus, A. McCampbell, G. L. Shipley, D. S. Loose, G. M.
- 491 Stancel, J. H. Pickar and P. J. A. Davies: Identification of a Novel Estrogen-Regulated
- 492 Gene, EIG121, Induced by Hormone Replacement Therapy
- 493 and Differentially Expressed in Type I and Type II Endometrial Cancer. Clinical
- 494 Cancer Research, 11(23), 8258 (2005) doi:10.1158/1078-0432.CCR-05-1189

- 495 30. J. M. Kang, S. Park, S. J. Kim, H. Kim, B. Lee, J. Kim, J. Park, S. T. Kim, H.-K.
- 496 Yang, W. H. Kim and S.-J. Kim: KIAA1324 Suppresses Gastric Cancer Progression
- 497 by Inhibiting the Oncoprotein GRP78. Cancer Research, 75(15), 3087 (2015)
- 498 doi:10.1158/0008-5472.CAN-14-3751
- 499 31. S. N. Westin, R. R. Broaddus, L. Deng, A. McCampbell, K. H. Lu, R. A. Lacour,
- 500 M. R. Milam, D. L. Urbauer, P. Mueller, J. H. Pickar and D. S. Loose: Molecular
- 501 clustering of endometrial carcinoma based on estrogen-induced gene expression.
- 502 Cancer biology & therapy, 8(22), 2126-2135 (2009) doi:10.4161/cbt.8.22.9740
- 503 32. D. S. Oh, M. A. Troester, J. Usary, Z. Hu, X. He, C. Fan, J. Wu, L. A. Carey and
- 504 C. M. Perou: Estrogen-Regulated Genes Predict Survival in Hormone
- Receptor-Positive Breast Cancers. Journal of Clinical Oncology, 24(11), 1656-1664
- 506 (2006) doi:10.1200/JCO.2005.03.2755
- 33. M. P. Schlumbrecht, S.-S. Xie, G. L. Shipley, D. L. Urbauer and R. R. Broaddus:
- Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous
- 509 carcinoma of the ovary/peritoneum. Modern Pathology, 24(3), 453-462 (2011)
- 510 doi:10.1038/modpathol.2010.211
- 34. L. Deng, J. Feng and R. R. Broaddus: The novel estrogen-induced gene EIG121
- 512 regulates autophagy and promotes cell survival under stress. Cell death & disease,
- 513 1(4), e32-e32 (2010) doi:10.1038/cddis.2010.9
- 35. G. Zhu, L. Pei, H. Yin, F. Lin, X. Li, X. Zhu, W. He and X. Gou: Profiles of
- 515 tumor-infiltrating immune cells in renal cell carcinoma and their clinical implications.
- 516 Oncology letters, 18(5), 5235-5242 (2019) doi:10.3892/ol.2019.10896
- 36. S. Crotty: Follicular Helper CD4 T Cells (TFH). Annual Review of Immunology,
- 518 29(1), 621-663 (2011) doi:10.1146/annurev-immunol-031210-101400
- 519 37. S. Crotty: T Follicular Helper Cell Biology: A Decade of Discovery and Diseases.
- 520 *Immunity*, 50(5), 1132-1148 (2019) doi:10.1016/j.immuni.2019.04.011
- 38. R. J. Johnston, A. C. Poholek, D. DiToro, I. Yusuf, D. Eto, B. Barnett, A. L. Dent,
- 522 J. Craft and S. Crotty: Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of
- 523 T follicular helper cell differentiation. Science (New York, N.Y.), 325(5943),
- 524 1006-1010 (2009) doi:10.1126/science.1175870
- 525 39. P. Amé-Thomas, J. Le Priol, H. Yssel, G. Caron, C. Pangault, R. Jean, N. Martin,
- 526 T. Marafioti, P. Gaulard, T. Lamy, T. Fest, G. Semana and K. Tarte: Characterization
- of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of
- 528 malignant B cells. *Leukemia*, 26(5), 1053-1063 (2012) doi:10.1038/leu.2011.301
- 529 40. Z. Guo, H. Liang, Y. Xu, L. Liu, X. Ren, S. Zhang, S. Wei and P. Xu: The Role of
- 530 Circulating T Follicular Helper Cells and Regulatory Cells in Non-Small Cell Lung
- 531 Cancer Patients. Scandinavian Journal of Immunology, 86(2), 107-112 (2017)
- 532 doi:https://doi.org/10.1111/sji.12566
- 41. C. Gu-Trantien, S. Loi, S. Garaud, C. Equeter, M. Libin, A. de Wind, M. Ravoet,
- H. Le Buanec, C. Sibille, G. Manfouo-Foutsop, I. Veys, B. Haibe-Kains, S. K. Singhal,
- 535 S. Michiels, F. Rothé, R. Salgado, H. Duvillier, M. Ignatiadis, C. Desmedt, D. Bron, D.
- 536 Larsimont, M. Piccart, C. Sotiriou and K. Willard-Gallo: CD4 ☐ follicular helper T

- 537 cell infiltration predicts breast cancer survival. The Journal of clinical investigation,
- 538 123(7), 2873-2892 (2013) doi:10.1172/JCI67428
- 42. G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner, Anna C. Obenauf,
- H. Angell, T. Fredriksen, L. Lafontaine, A. Berger, P. Bruneval, Wolf H. Fridman, C.
- Becker, F. Pagès, Michael R. Speicher, Z. Trajanoski and J. Galon: Spatiotemporal
- 542 Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human
- 543 Cancer. *Immunity*, 39(4), 782-795 (2013)
- 544 doi:https://doi.org/10.1016/j.immuni.2013.10.003
- 545 43. B. Frossi, F. Mion, C. Tripodo, M. P. Colombo and C. E. Pucillo: Rheostatic
- 546 Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses.
- 547 Trends in Immunology, 38(9), 648-656 (2017)
- 548 doi:https://doi.org/10.1016/j.it.2017.04.001
- 549 44. E. Z. M. da Silva, M. C. Jamur and C. Oliver: Mast cell function: a new vision of
- an old cell. The journal of histochemistry and cytochemistry: official journal of the
- 551 Histochemistry Society, 62(10), 698-738 (2014) doi:10.1369/0022155414545334
- 45. C. Wang, X. Tang, J. Wang and Y. Xu: Patterns of immune infiltration in lung
- adenocarcinoma revealed a prognosis-associated microRNA-mast cells network.
- 554 Human Cell, 33(1), 205-219 (2020) doi:10.1007/s13577-019-00300-1
- 46. N. Rohr-Udilova, F. Klinglmüller, R. Schulte-Hermann, J. Stift, M. Herac, M.
- 556 Salzmann, F. Finotello, G. Timelthaler, G. Oberhuber, M. Pinter, T. Reiberger, E.
- Jensen-Jarolim, R. Eferl and M. Trauner: Deviations of the immune cell landscape
- between healthy liver and hepatocellular carcinoma. Scientific reports, 8(1),
- 559 6220-6220 (2018) doi:10.1038/s41598-018-24437-5

561

562

563

564

565

566

567

568

569

570 571 572 573 574 **Figure Captions** 575 576 **Figure 1** Flowchart of the analysis process. 577 578 Figure 2 Genes differentially expressed in 506 KIRC tissues versus 71 normal 579 adjacent tissues. Provided are the heatmap (a) and the volcano plot (b) of 357 580 differentially expressed lncRNAs between the two groups; the heatmap (c) and the 581 volcano plot (d) of 132 differentially expressed miRNAs between the two groups; and 582 the heatmap (e) and the volcano plot (f) of 3092 differentially expressed 583 protein-coding genes between the two groups; and the composition of differentially 584 expressed genes (g). All differentially expressed genes had a log (fold-change) > 1.0 585 or < -1.0 and the overall of FDR < 0.05. 586 587 Figure 3 (a) The KIRC related ceRNA network consisting of 12 lncRNAs, 25 588 miRNAs and 136 mRNAs. (b-j) The K-M survival curves of the top three lncRNAs, 589 miRNAs and mRNAs: PVT1 (b), AC005154.1 (c), AC015813.1 (d), hsa-miR-21-5p 590 (e), hsa-miR-130b-3p (f), hsa-miR-204-5p (g), MXD3 (h), VPS13D (i) and KCNN4 591 (j). 592 593 Figure 4 The Cox proportional hazards regression model (a) based on RNAs screened

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

by Lasso regression analysis (b and c) in the ceRNA network. Seven potential prognosis related RNAs were integrated into the Cox proportional hazards regression model. The nomogram (e) was constructed based on the model. The ROC (d) and calibration curves (f) indicate the acceptable accuracy (AUCs of 1, 3 and 5-year survivals: 0.779, 0.747 and 0.772) and discrimination of the nomogram. **P* < 0.05; ***P* < 0.010; ****P* < 0.001. **Figure 5** The composition (a) and heatmap (b) of immune cells estimated by the CIBERSORT algorithm in five normal adjacent tissues and 206 KIRC tissues. The violin plot of immune cells (c) compares cells' proportion between the two groups. Figure 6 The Cox proportional hazards regression model (a) based on immune cells screened by Lasso regression analysis (b and c). Tfh cells and resting mast cells were integrated into the Cox proportional hazards regression model. The nomogram (e) was constructed based on the model. The ROC (d) and the calibration curves (f) indicate the acceptable accuracy (AUCs of 1, 3 and 5-year survivals: 0.603, 0.642 and 0.607) and discrimination of the nomogram. **P* < 0.05; ***P* < 0.010; ****P* < 0.001. Figure 7 Co-expression heatmap of all immune cells in KIRC (a); the co-expression heatmap of the RNAs and immune cells in the two Cox proportional hazards regression models (b); the significant results of Pearson correlation coefficients between the RNAs and immune cells: Tfh cells and LINC00894 (c); Tfh cells and KIAA1324 (d); resting mast cells and LINC00894 (e); resting mast cells and KIAA1324 (f).

Table 1 Hypergeometric testing and correlation analysis results of ceRNAs pairs

lncRNAs	mRNAs	miRNAs	Hypergeometric test P	Correlation P
AC005154.1	KAT2A	hsa-miR-122-5p	0.042851557	1.32E-95
AC015813.1	SLC16A1	hsa-miR-590-3p	0.0433213	0.019445968
AC015813.1	FHOD1	hsa-miR-590-3p	0.007220217	4.09E-19
AC015813.1	E2F8	hsa-miR-590-3p	0.025270758	1.22E-09
AC015813.1	SERPINB9	hsa-miR-590-3p	0.025270758	0.000636067
AC015813.1	COL5A2	hsa-miR-590-3p	0.014440433	0.015398545
AC015813.1	BRIP1	hsa-miR-590-3p	0.003610108	5.18E-09
AC015813.1	ESCO2	hsa-miR-590-3p	0.02166065	0.009163956
AC015813.1	TXLNB	hsa-miR-590-3p	0.003610108	0.020621823

AC015813.1	PSTPIP2	hsa-miR-590-3p	0.003610108	0.000108913
AC015813.1	SNRNP70	hsa-miR-590-3p	0.003610108	4.80E-73
AC016876.2	TNFRSF10B	hsa-miR-133a-3p	0.003810813	9.33E-39
AC016876.2	MYO9B	hsa-miR-133a-3p	0.000392403	1.06E-53
AC016876.2	PREX1	hsa-miR-133a-3p	0.013191013	2.17E-22
AC016876.2	CAPN15	hsa-miR-133a-3p	0.027474351	1.51E-34
AC016876.2	CORO1C	hsa-miR-133a-3p	0.001461641	2.06E-36
AC016876.2	FJX1	hsa-miR-133a-3p	0.036258784	6.66E-19
AC016876.2	NDRG1	hsa-miR-133a-3p	0.010361047	1.00E-11
AC016876.2	VKORC1	hsa-miR-133a-3p	0.001165794	1.01E-27
AC016876.2	TMEM200B	hsa-miR-133a-3p	0.013191013	9.12E-19
AC016876.2	RSRP1	hsa-miR-133a-3p	0.000881161	6.23E-07

C1RL-AS1	SCARB1	hsa-miR-16-5p	0.001438811	1.64E-42
C1RL-AS1	VEGFA	hsa-miR-16-5p	0.030764401	2.81E-61
C1RL-AS1	AHNAK2	hsa-miR-16-5p	0.000392403	7.17E-21
C1RL-AS1	PTHLH	hsa-miR-16-5p	0.009888558	1.10E-07
C1RL-AS1	RELT	hsa-miR-16-5p	0.000732486	3.61E-14
C1RL-AS1	PFKFB4	hsa-miR-16-5p	0.004002511	6.80E-27
C1RL-AS1	CCND1	hsa-miR-16-5p	0.046303563	7.81E-25
C1RL-AS1	APLN	hsa-miR-16-5p	0.000549364	2.74E-25
C1RL-AS1	SH2D2A	hsa-miR-16-5p	0.000732486	7.13E-19
C1RL-AS1	SEL1L3	hsa-miR-16-5p	0.012975462	1.23E-23
C1RL-AS1	UNC5B	hsa-miR-16-5p	0.000392403	1.58E-15
C1RL-AS1	PHLDA3	hsa-miR-16-5p	0.001177209	0.000714118

C1RL-AS1	SLC41A2	hsa-miR-16-5p	0.000941767	1.16E-10
C1RL-AS1	GRB10	hsa-miR-16-5p	0.022523937	4.08E-21
C1RL-AS1	SLC2A3	hsa-miR-16-5p	0.013812588	1.39E-09
C1RL-AS1	MYBL1	hsa-miR-16-5p	0.049468948	1.21E-08
C1RL-AS1	ANLN	hsa-miR-16-5p	0.004002511	7.40E-05
C1RL-AS1	OTOGL	hsa-miR-16-5p	0.000392403	1.38E-08
C1RL-AS1	KCNJ2	hsa-miR-16-5p	0.019384712	9.72E-07
C1RL-AS1	CNTNAP1	hsa-miR-16-5p	0.003139225	6.23E-12
C1RL-AS1	NRARP	hsa-miR-16-5p	0.023622665	4.17E-13
C1RL-AS1	CREB5	hsa-miR-16-5p	0.013812588	5.44E-48
C1RL-AS1	ATAD5	hsa-miR-16-5p	0.042928897	2.56E-37
C1RL-AS1	INSR	hsa-miR-16-5p	0.009182232	1.03E-20

C1RL-AS1	SIPA1L2	hsa-miR-16-5p	0.006043007	9.08E-08
C1RL-AS1	AATK	hsa-miR-16-5p	0.000549364	1.52E-28
C1RL-AS1	RFLNB	hsa-miR-16-5p	0.000941767	5.34E-05
C1RL-AS1	SPRY4	hsa-miR-16-5p	0.002746822	8.52E-14
C1RL-AS1	ARL10	hsa-miR-16-5p	0.001438811	1.17E-11
C1RL-AS1	ANKRD13B	hsa-miR-16-5p	0.003139225	7.32E-16
C1RL-AS1	SNAP25	hsa-miR-16-5p	0.002380579	1.30E-19
C1RL-AS1	LY6E	hsa-miR-16-5p	0.000941767	1.68E-17
C1RL-AS1	CDK5R1	hsa-miR-16-5p	0.013812588	1.69E-16
C1RL-AS1	CLCN5	hsa-miR-16-5p	0.006618532	0.020236846
C1RL-AS1	BDNF	hsa-miR-16-5p	0.010621043	8.30E-09
C1RL-AS1	IRX3	hsa-miR-16-5p	0.000732486	1.79E-37

C1RL-AS1	PLAGL1	hsa-miR-16-5p	0.004473395	1.30E-23
C1RL-AS1	IRF4	hsa-miR-16-5p	0.004970439	2.67E-12
C1RL-AS1	TSPYL2	hsa-miR-16-5p	0.002380579	1.01E-20
C1RL-AS1	TLL1	hsa-miR-16-5p	0.007848062	5.19E-19
C1RL-AS1	KCNN4	hsa-miR-16-5p	0.000732486	4.96E-09
C1RL-AS1	TRIM36	hsa-miR-16-5p	0.015565322	0.000352309
C1RL-AS1	CBFA2T3	hsa-miR-16-5p	0.004970439	6.86E-13
C1RL-AS1	TSC22D3	hsa-miR-16-5p	0.012975462	3.07E-05
C1RL-AS1	SNCG	hsa-miR-16-5p	0.001726574	0.02336615
EPB41L4A-AS1	TNFRSF10B	hsa-miR-93-5p	0.005296055	0.000309792
EPB41L4A-AS1	IKBIP	hsa-miR-93-5p	0.049992152	1.07E-06
H19	EGLN3	hsa-miR-130b-3p	0.025364366	0.030923622

H19	UXS1	hsa-miR-130b-3p	0.017341521	0.000663666
H19	USP46	hsa-miR-130b-3p	0.024521918	0.043104031
H19	ACSL4	hsa-miR-130b-3p	0.049356887	0.046472711
H19	LDLRAD3	hsa-miR-130b-3p	0.017341521	2.91E-06
H19	BMP6	hsa-miR-130b-3p	0.021136246	1.44E-05
H19	RASD1	hsa-miR-130b-3p	0.001092495	0.000237995
H19	NHSL1	hsa-miR-130b-3p	0.002162624	0.000635296
H19	C8orf4	hsa-miR-130b-3p	0.040677495	1.83E-10
H19	MAP3K12	hsa-miR-130b-3p	0.000287237	0.006322847
H19	VPS13D	hsa-miR-130b-3p	0.00310273	0.022110203
H19	PXDN	hsa-miR-130b-3p	0.001415171	2.64E-12
H19	PMEPA1	hsa-miR-130b-3p	0.001092495	2.21E-10

H19	WNK3	hsa-miR-130b-3p	0.000207327	0.000409846
H19	PFKFB3	hsa-miR-130b-3p	0.004199543	0.001757017
H19	TCF4	hsa-miR-130b-3p	0.000309855	2.83E-07
H19	HECW2	hsa-miR-130b-3p	0.001092495	0.000515485
H19	LRRC41	hsa-miR-130b-3p	0.008478302	0.004641957
H19	KLHL3	hsa-miR-130b-3p	0.035134428	0.004796761
H19	LDLR	hsa-miR-130b-3p	0.002491825	6.36E-13
H19	SCARA3	hsa-miR-130b-3p	0.005054152	6.50E-06
LINC00893	SCARB1	hsa-miR-125b-5p, hsa-miR-125a-5p	0.001438811	0.000105621
LINC00893	VEGFA	hsa-miR-125b-5p, hsa-miR-125a-5p	0.030764401	8.10E-26
LINC00893	MYEOV	hsa-miR-125b-5p	0.014414273	6.39E-05
LINC00893	SOX11	hsa-miR-125b-5p, hsa-miR-125a-5p	0.015565322	9.42E-07

LINC00893	PRDM1	hsa-miR-125b-5p, hsa-miR-125a-5p	0.032046251	0.001791829
LINC00893	GJC1	hsa-miR-125b-5p, hsa-miR-125a-5p	0.003139225	1.58E-05
LINC00893	OLFML2A	hsa-miR-125b-5p, hsa-miR-125a-5p	0.000156961	0.009879398
LINC00893	LIMD2	hsa-miR-125b-5p, hsa-miR-125a-5p	0.006043007	8.66E-13
LINC00893	GRB10	hsa-miR-125b-5p, hsa-miR-125a-5p	0.022523937	0.004617551
LINC00893	TNFAIP3	hsa-miR-125b-5p, hsa-miR-125a-5p	0.02040496	0.000292635
LINC00893	KMT5C	hsa-miR-125b-5p, hsa-miR-125a-5p	0.006618532	1.47E-81
LINC00893	PDE7A	hsa-miR-125b-5p, hsa-miR-125a-5p	0.019384712	2.94E-13
LINC00893	PLAGL1	hsa-miR-125b-5p, hsa-miR-125a-5p	0.004473395	1.50E-09
LINC00893	IRF4	hsa-miR-125b-5p, hsa-miR-125a-5p	0.004970439	8.51E-05
LINC00893	FAM118A	hsa-miR-125b-5p, hsa-miR-125a-5p	0.005493643	1.23E-43
LINC00894	GRIN2D	hsa-miR-342-3p	0.02166065	0.020258812

MALAT1	ZNF395	hsa-miR-429, hsa-miR-200c-3p	0.033565927	0.009006143
MALAT1	SCD	hsa-miR-200b-3p, hsa-miR-200a-3p, hsa-miR-429,	0.039289444	0.011807116
		hsa-miR-200c-3p, hsa-miR-141-3p		
MALAT1	EZH2	hsa-miR-217	0.039289444	6.86E-14
MALAT1	MXD3	hsa-miR-200b-3p, hsa-miR-429, hsa-miR-200c-3p	0.001707738	3.90E-34
MALAT1	BAZ1A	hsa-miR-590-3p	0.018390826	7.26E-05
MALAT1	SIX1	hsa-miR-200b-3p, hsa-miR-200a-3p, hsa-miR-429,	0.00025153	4.87E-06
	2222	hsa-miR-200c-3p, hsa-miR-141-3p, hsa-miR-590-3p		
MALAT1	KCNJ2	hsa-miR-1-3p, hsa-miR-1271-5p, hsa-miR-590-3p	0.000680978	0.01227854
MALAT1	RUNX2	hsa-miR-203a-3p, hsa-miR-217, hsa-miR-590-3p	0.027070651	0.007921587
MALAT1	PDE7A	hsa-miR-1-3p	0.031465278	1.64E-07
MALAT1	CCND2	hsa-miR-200a-3p, hsa-miR-141-3p, hsa-miR-1-3p,	0.002367103	0.005749454

hsa-miR-1271-5p

MALAT1	FOXF1	hsa-miR-200b-3p, hsa-miR-429, hsa-miR-200c-3p	0.033565927	0.001701238
MALAT1	KIAA1324	hsa-miR-1271-5p	0.040612149	0.018453328
NEAT1	STC2	hsa-miR-181b-5p, hsa-miR-204-5p	0.005508592	0.022782701
NEAT1	GJC1	hsa-let-7e-5p, hsa-let-7g-5p	0.010508709	0.038550157
NEAT1	ADM	hsa-miR-181b-5p	0.028501136	9.33E-08
NEAT1	EZH2	hsa-let-7e-5p, hsa-let-7g-5p	0.008654278	1.27E-12
NEAT1	AURKB	hsa-let-7e-5p, hsa-let-7g-5p	0.00048449	0.032101352
NEAT1	KIF21B	hsa-let-7e-5p, hsa-let-7g-5p	0.003786827	3.94E-06
NEAT1	INTS6L	hsa-let-7e-5p, hsa-let-7g-5p	0.001348287	1.00E-46
NEAT1	DTX2	hsa-let-7e-5p, hsa-let-7g-5p	0.022864398	0.003873252
NEAT1	LIMD2	hsa-let-7e-5p, hsa-let-7g-5p	0.001852057	0.023584192

NEAT1	NGF	hsa-let-7e-5p, hsa-let-7g-5p	0.00048449	0.036481826
NEAT1	POLQ	hsa-miR-181b-5p, hsa-let-7e-5p	0.026346413	4.13E-05
NEAT1	POU2F2	hsa-let-7e-5p, hsa-let-7g-5p	0.00772659	0.046579228
NEAT1	APBB3	hsa-let-7e-5p, hsa-let-7g-5p	0.003786827	1.03E-93
NEAT1	MAPK11	hsa-let-7e-5p, hsa-let-7g-5p	0.00048449	0.020903367
NEAT1	FBXO41	hsa-miR-181b-5p	0.000291346	0.00718285
NEAT1	PITPNM3	hsa-let-7e-5p, hsa-let-7g-5p	0.022864398	0.000826877
NEAT1	NPHP3	hsa-let-7e-5p, hsa-let-7g-5p	0.022864398	7.31E-68
NEAT1	DNA2	hsa-let-7e-5p, hsa-let-7g-5p	0.003786827	1.69E-34
NEAT1	AMT	hsa-let-7e-5p, hsa-let-7g-5p	0.000906364	0.001503922
NEAT1	SLC25A37	hsa-miR-181b-5p	0.002491825	1.48E-28
NEAT1	FAM118A	hsa-let-7e-5p, hsa-let-7g-5p	0.034971322	7.22E-34

NEAT1	AASS	hsa-let-7e-5p, hsa-let-7g-5p	0.00048449	1.39E-05
NEAT1	CELSR3	hsa-miR-181b-5p, hsa-miR-204-5p	0.00026878	5.77E-21
NEAT1	KIFC2	hsa-let-7e-5p, hsa-let-7g-5p	0.002491825	4.59E-65
NEAT1	RNF165	hsa-let-7e-5p, hsa-let-7g-5p	0.00587435	2.76E-05
NEAT1	SLC25A27	hsa-let-7e-5p, hsa-let-7g-5p	0.001554187	2.36E-89
PVT1	TNFRSF10B	hsa-miR-93-5p	0.005296055	1.15E-70
PVT1	IKBIP	hsa-miR-93-5p	0.049992152	4.69E-68
PVT1	TET3	hsa-miR-93-5p, hsa-miR-20b-5p	0.000351901	6.58E-37
PVT1	CCND2	hsa-miR-93-5p, hsa-miR-20b-5p	0.000180512	2.67E-22
SNHG1	NETO2	hsa-miR-21-5p	0.041029046	3.64E-18
SNHG1	CDKN2C	hsa-miR-154-5p	0.02166065	9.52E-06
SNHG1	GBP1	hsa-miR-21-5p	0.02166065	0.014315805

SNHG1 ADGRG2 hsa-miR-21-5p 0.00064624 1.35E-05

621

















